Pricing Pressures and Offshoring Research Work
Monday, September 29th, 2008The high price of drugs is what fuels the capital flow into biotechs - venture capitalists make big bets and, when a bet does pay off, they need a big return to cover the other losses. High prices for new discoveries is what keeps the returns high. As pricing pressures increase, biotechnology companies look for other ways to reach profitability. The movement to “off shore” biotech jobs to places such as India and China, connects the profitability dots on two fronts.
First, there are straight cost savings to be had. Some of the industry’s largest players (Eli Lilly, Amgen, Merck and others) are seeking a similar mix of low-cost, highly educated labor that made the tech sectore move to India in a big way several years ago. Second, the business has shifted and the heat is on to come up with market changing products that will drive desperately needed revenue growth. In addition to gobbling up smaller, successful biotechs, setting up overseas partnerships for collaborative research is another strategy to plugging the gap that expiring patents leave behind.
US biopharma companies are moving research jobs off shore and we don’t expect the trend to slow anytime soon.
